Evidence map›Paper›PMID 36276913›Full record

ArticleCanadian journal of gastroenterology & hepatology2022

Finding Cases of Hepatitis C for Treatment Using Automated Screening in the Emergency Department is Effective, but What Is the Cost?

David Stephen Prince, Julia Di Girolamo, Joseph Louis Pipicella, Melissa Bagatella, Tahrima Kayes, Frank Alvaro, Michael Maley, Hong Foo, Paul MacConachie Middleton, Miriam Tania Levy

Open access · goldAbstract read
In one paragraph

Article in Canadian journal of gastroenterology & hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

David Stephen PrinceLiverpool Hospital, Sydney, NSW, Australia.ORCID 0000-0001-8087-0548
Julia Di GirolamoLiverpool Hospital, Sydney, NSW, Australia.
Joseph Louis PipicellaLiverpool Hospital, Sydney, NSW, Australia.ORCID 0000-0002-1796-918X
Melissa BagatellaLiverpool Hospital, Sydney, NSW, Australia.
Tahrima KayesLiverpool Hospital, Sydney, NSW, Australia.
Frank AlvaroLiverpool Hospital, Sydney, NSW, Australia.
Michael MaleyLiverpool Hospital, Sydney, NSW, Australia.
Hong FooLiverpool Hospital, Sydney, NSW, Australia.
Paul MacConachie MiddletonLiverpool Hospital, Sydney, NSW, Australia.ORCID 0000-0003-0760-1098
Miriam Tania LevyLiverpool Hospital, Sydney, NSW, Australia.ORCID 0000-0001-9329-8018
Liverpool Hospital · AUNew South Wales Department of Health · AUThe University of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Case detection remains a major challenge for hepatitis C virus (HCV) elimination. We have previously published results from a pilot of an emergency department (ED) semiautomated screening program, SEARCH; Screening Emergency Admissions at Risk of Chronic HCV. Several refinements to SEARCH have been developed to streamline and reduce cost. All direct costs of HCV testing until direct-acting antiviral (DAA) therapy initiation were calculated. Cost was assessed in 2018 Australian Dollars. A cost analysis of the initial program and refinements are presented. Sensitivity analysis to understand impact of variation in staff time, laboratory test cost, changes in HCV antibody (Ab) prevalence, RNA positivity percentage, and rate of linkage to care was conducted. Impact of refinements (SEARCH (2)) to cost is presented. The total SEARCH pilot, testing 5000 patients was estimated to cost $110,549.52 (range $92,109.79-$129,581.24) comprising of $68,278.67 for HCV Ab testing, $21,568.99 for follow-up and linkage to care of positive patients and $20,701.86 to prepare HCV RNA positive patients for treatment. Internal program refinements resulted in a 25% cost reduction. Following refinements, the cost of HCV antibody screening was $8.46 per test and the total cost per positive HCV Ab, positive HCV RNA, and per treated patient were $611.77, $2,168.64, and $3,566.11, respectively. Our sensitivity analysis indicates costs per HCV case found are modest so long as HCV Ab prevalence was at least 1%. ED screening is an affordable strategy for HCV case detection and elimination.

Indexed as

Hepatitis CHepatitis C, ChronicAntiviral AgentsAustraliaEmergency Service, HospitalHepacivirusHepatitis C AntibodiesHumansMass ScreeningRNAAntiviral AgentsHepatitis C AntibodiesRNA

Identifiers

PMID36276913
PMCPMC9586809
OpenAlexW4306248579

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.